RU2761631C2 - Белки rsv в предшествующей слиянию конформации и их применение - Google Patents
Белки rsv в предшествующей слиянию конформации и их применение Download PDFInfo
- Publication number
- RU2761631C2 RU2761631C2 RU2015142981A RU2015142981A RU2761631C2 RU 2761631 C2 RU2761631 C2 RU 2761631C2 RU 2015142981 A RU2015142981 A RU 2015142981A RU 2015142981 A RU2015142981 A RU 2015142981A RU 2761631 C2 RU2761631 C2 RU 2761631C2
- Authority
- RU
- Russia
- Prior art keywords
- rsv
- protein
- immunogen
- polypeptide
- fusion
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 9
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 9
- 230000002163 immunogen Effects 0.000 claims abstract 41
- 230000028993 immune response Effects 0.000 claims abstract 8
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims abstract 6
- 230000001939 inductive effect Effects 0.000 claims abstract 5
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 42
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims 30
- 239000013598 vector Substances 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 8
- 239000002105 nanoparticle Substances 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 235000018102 proteins Nutrition 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 102000008857 Ferritin Human genes 0.000 claims 5
- 108050000784 Ferritin Proteins 0.000 claims 5
- 238000008416 Ferritin Methods 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000005829 trimerization reaction Methods 0.000 claims 5
- 241000283690 Bos taurus Species 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 241000711895 Bovine orthopneumovirus Species 0.000 claims 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 2
- 108030005146 Sulfur oxygenase/reductases Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
- -1 encapsulin Proteins 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108010068996 6,7-dimethyl-8-ribityllumazine synthase Proteins 0.000 claims 1
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000711408 Murine respirovirus Species 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 102000002067 Protein Subunits Human genes 0.000 claims 1
- 108010001267 Protein Subunits Proteins 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- 241000710961 Semliki Forest virus Species 0.000 claims 1
- 241000710960 Sindbis virus Species 0.000 claims 1
- 230000029662 T-helper 1 type immune response Effects 0.000 claims 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 abstract 2
- 102100023206 Neuromodulin Human genes 0.000 abstract 1
- 101710132548 Protein F1 Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18523—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780910P | 2013-03-13 | 2013-03-13 | |
| US61/780,910 | 2013-03-13 | ||
| US201361798389P | 2013-03-15 | 2013-03-15 | |
| US61/798,389 | 2013-03-15 | ||
| US201361857613P | 2013-07-23 | 2013-07-23 | |
| US61/857,613 | 2013-07-23 | ||
| US201361863909P | 2013-08-09 | 2013-08-09 | |
| US61/863,909 | 2013-08-09 | ||
| PCT/US2014/026714 WO2014160463A1 (en) | 2013-03-13 | 2014-03-13 | Prefusion rsv f proteins and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021132097A Division RU2852571C2 (ru) | 2013-03-13 | 2014-03-13 | Белки rsv f в предшествующей слиянию конформации и их применение |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2015142981A RU2015142981A (ru) | 2017-04-17 |
| RU2015142981A3 RU2015142981A3 (enExample) | 2018-03-14 |
| RU2761631C2 true RU2761631C2 (ru) | 2021-12-13 |
Family
ID=51625430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015142981A RU2761631C2 (ru) | 2013-03-13 | 2014-03-13 | Белки rsv в предшествующей слиянию конформации и их применение |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10017543B2 (enExample) |
| EP (2) | EP2970398B1 (enExample) |
| JP (4) | JP6703475B2 (enExample) |
| KR (3) | KR102766946B1 (enExample) |
| CN (2) | CN112851766A (enExample) |
| AU (5) | AU2014243756B2 (enExample) |
| CA (1) | CA2902877A1 (enExample) |
| DK (1) | DK2970398T3 (enExample) |
| ES (1) | ES2981623T3 (enExample) |
| FI (1) | FI2970398T3 (enExample) |
| HR (1) | HRP20240996T1 (enExample) |
| HU (1) | HUE067333T2 (enExample) |
| LT (1) | LT2970398T (enExample) |
| MX (2) | MX385818B (enExample) |
| PL (1) | PL2970398T3 (enExample) |
| PT (1) | PT2970398T (enExample) |
| RS (1) | RS65760B1 (enExample) |
| RU (1) | RU2761631C2 (enExample) |
| SI (1) | SI2970398T1 (enExample) |
| SM (1) | SMT202400297T1 (enExample) |
| WO (1) | WO2014160463A1 (enExample) |
Families Citing this family (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| CA2900110A1 (en) | 2013-02-01 | 2014-08-07 | Medimmune, Llc | Respiratory syncytial virus f protein epitopes |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| AU2014243756B2 (en) * | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| EP3798310A1 (en) | 2013-03-14 | 2021-03-31 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
| KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
| US10899800B2 (en) | 2013-04-25 | 2021-01-26 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| BR112015031509B1 (pt) * | 2013-06-17 | 2023-05-09 | Janssen Vaccines & Prevention B.V. | Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende |
| WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| US10125172B2 (en) | 2013-07-25 | 2018-11-13 | Calder Biosciences Inc. | Conformationally stabilized RSV pre-fusion F proteins |
| KR20160044566A (ko) | 2013-08-21 | 2016-04-25 | 큐어백 아게 | 호흡기 세포융합 바이러스 |
| EP3049107A1 (en) * | 2013-09-24 | 2016-08-03 | Massachusetts Institute of Technology | Self-assembled nanoparticle vaccines |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| WO2016118642A1 (en) | 2015-01-20 | 2016-07-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof |
| EP3250233A4 (en) | 2015-01-29 | 2018-07-25 | Agency for Science, Technology and Research | Nanocapsules carrying chikungunya-associated peptides |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| BR112017027448A2 (pt) | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
| WO2017005848A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| FR3041962B1 (fr) * | 2015-10-01 | 2018-01-05 | Lab Francais Du Fractionnement | Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie |
| HRP20220872T1 (hr) | 2015-10-22 | 2022-12-23 | Modernatx, Inc. | Cjepiva protiv respiratornih virusa |
| TN2018000154A1 (en) * | 2015-10-22 | 2019-10-04 | Modernatx Inc | Respiratory syncytial virus vaccine |
| US11235050B2 (en) | 2015-10-29 | 2022-02-01 | Emory University | Chimeric RSV, immunogenic compositions, and methods of use |
| MY205060A (en) * | 2015-12-23 | 2024-09-30 | Pfizer | Rsv f protein mutants |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| WO2017172890A1 (en) * | 2016-03-29 | 2017-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substitutions-modified prefusion rsv f proteins and their use |
| EA039095B1 (ru) | 2016-04-05 | 2021-12-03 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизированные растворимые f-белки rsv до слияния |
| EA201892250A1 (ru) | 2016-04-05 | 2019-03-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| IL245059A0 (en) | 2016-04-12 | 2016-06-30 | Technion Res & Dev Foundation | Electrospun scaffolds from extracellular matrix |
| CN109311946A (zh) * | 2016-05-30 | 2019-02-05 | 扬森疫苗与预防公司 | 稳定化的融合前rsv f蛋白 |
| US10961283B2 (en) | 2016-06-27 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| CN106119287B (zh) * | 2016-08-29 | 2019-10-11 | 广东华南疫苗股份有限公司 | 一种表达呼吸道合胞病毒f蛋白的重组载体及方法 |
| EP3518967A4 (en) | 2016-10-03 | 2020-04-29 | University of Massachusetts | Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv) |
| EP3532096B1 (en) | 2016-10-25 | 2023-02-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Prefusion piv f immunogens and their use |
| JP7194104B2 (ja) * | 2016-10-26 | 2022-12-21 | シーダーズ―シナイ メディカル センター | 抗ｔｌ１ａモノクローナル抗体の中和 |
| TWI683826B (zh) * | 2016-11-22 | 2020-02-01 | 國立臺灣大學 | 重組ｒｓｖ抗原 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| WO2018109220A2 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| CN108265079A (zh) * | 2017-01-02 | 2018-07-10 | 刘昕 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
| US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018175518A1 (en) * | 2017-03-22 | 2018-09-27 | The Scripps Research Institute | Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv) |
| PT3606942T (pt) | 2017-04-04 | 2025-09-01 | Inst Res Biomedicine | Nanoestruturas proteicas de automontagem que apresentam proteínas f de paramixovírus e/ou pneumovírus e sua utilização |
| AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| FR3066920A1 (fr) | 2017-05-30 | 2018-12-07 | Glaxosmithkline Biologicals S.A. | Nouveaux procedes de fabrication d'un adjuvant |
| AU2018285412B2 (en) | 2017-06-14 | 2022-06-23 | Universität Zürich | Cyclic peptides for protection against respiratory syncytial virus |
| CN119529036A (zh) * | 2017-08-07 | 2025-02-28 | 考尔德生物科技有限公司 | 构象稳定的rsv预融合f蛋白 |
| CN111163800A (zh) | 2017-09-15 | 2020-05-15 | 扬森疫苗与预防公司 | 用于安全诱导针对rsv的免疫的方法 |
| JP2019092481A (ja) * | 2017-11-27 | 2019-06-20 | 国立大学法人東京工業大学 | ヘテロタンパク質ケージ |
| MX2020005481A (es) | 2017-12-01 | 2020-12-07 | Glaxosmithkline Biologicals Sa | Purificacion de saponina. |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| AU2019212237B2 (en) * | 2018-01-29 | 2024-12-12 | Merck Sharp & Dohme Llc | Stabilized RSV F proteins and uses thereof |
| AU2019228551B2 (en) | 2018-02-28 | 2025-07-24 | University Of Washington | Self-assembling nanostructure vaccines |
| US11623004B2 (en) | 2018-03-16 | 2023-04-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions and methods for vaccination against respiratory syncytial virus infection |
| JP7614841B2 (ja) * | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| CN112512565A (zh) * | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性流感-铁蛋白多肽 |
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| WO2019195316A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Ferritin proteins |
| US20210170017A1 (en) | 2018-04-17 | 2021-06-10 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| CA3098374A1 (en) | 2018-04-25 | 2019-10-31 | Prometheus Biosciences, Inc. | Optimized anti-tl1a antibodies |
| KR20210013571A (ko) | 2018-05-04 | 2021-02-04 | 스파이바이오테크 리미티드 | 백신 조성물 |
| CN110684747B (zh) * | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
| SG11202100194VA (en) | 2018-07-31 | 2021-02-25 | Glaxosmithkline Biologicals Sa | Antigen purification method |
| CN112930192A (zh) | 2018-08-03 | 2021-06-08 | 美国政府(由卫生和人类服务部的部长所代表) | 尼帕病毒免疫原及其用途 |
| US20210283238A1 (en) | 2018-08-07 | 2021-09-16 | Glaxosmithkline Biologicals Sa | Novel processes and vaccines |
| CR20210306A (es) * | 2018-11-13 | 2021-07-22 | Janssen Vaccines & Prevention Bv | Proteínas f de prefusión del vrs estabilizadas |
| CA3120102A1 (en) * | 2018-11-14 | 2020-05-22 | Rubryc Therapeutics, Inc. | Engineered cd25 polypeptides and uses thereof |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CN113543803B (zh) | 2019-02-28 | 2024-10-29 | Km生物医药股份公司 | Rsv f/g嵌合疫苗 |
| US20220235095A1 (en) | 2019-06-05 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Saponin purification |
| JP2022546813A (ja) | 2019-09-04 | 2022-11-09 | ユニヴァーシティ オブ ワシントン | パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用 |
| CA3158638A1 (en) | 2019-10-24 | 2021-04-29 | Prometheus Biosciences, Inc. | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| US20230053555A1 (en) * | 2019-12-11 | 2023-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Mumps and measles virus immunogens and their use |
| JP7385680B2 (ja) * | 2019-12-23 | 2023-11-22 | 田辺三菱製薬株式会社 | 変異型ｒｓｖ ｆタンパク質及びその利用 |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| JP2023513073A (ja) * | 2020-01-30 | 2023-03-30 | モデルナティエックス インコーポレイテッド | 呼吸器系ウイルス免疫化組成物 |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| CN116096407A (zh) * | 2020-04-29 | 2023-05-09 | 美国政府(由卫生和人类服务部的部长所代表) | 重组人偏肺病毒f蛋白及其用途 |
| MX2022015132A (es) | 2020-05-29 | 2023-03-08 | CureVac SE | Vacunas combinadas a base de acidos nucleicos. |
| EP4157345A4 (en) * | 2020-05-29 | 2024-09-11 | Board of Regents, The University of Texas System | GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF |
| WO2021249009A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Rsv vaccine compositions, methods, and uses thereof |
| JP2022023814A (ja) | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産された三量体型のｒｓｖタンパク質の精製方法 |
| JP2022023813A (ja) | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良 |
| CN112226444B (zh) * | 2020-08-25 | 2022-11-04 | 北京交通大学 | 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品 |
| JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| JP7660671B2 (ja) | 2020-10-09 | 2025-04-11 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 融合前安定化ｈｍｐｖ ｆタンパク質 |
| MX2023005018A (es) | 2020-10-28 | 2023-05-16 | Sanofi Pasteur | Liposomas que contienen un agonista de tlr4, preparacion y usos de los mismos. |
| CN112592928B (zh) * | 2020-12-31 | 2021-08-31 | 北京鼎成肽源生物技术有限公司 | 冠状病毒的融合基因、融合蛋白、重组载体、通用型dc疫苗及其制备方法 |
| KR20230147156A (ko) * | 2021-02-19 | 2023-10-20 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합 전 rsv fb 항원 |
| BR112023020237A2 (pt) | 2021-04-02 | 2023-12-19 | Bureau D?Etudes Biologiques Scient Et Medicales | Composição imunogênica e processo para preparar a mesma, estrutura metal-orgânica e uso da mesma |
| US12304929B2 (en) * | 2021-04-12 | 2025-05-20 | Sk Bioscience Co., Ltd. | Recombinant RSV live vaccine strain and the preparing method thereof |
| WO2022221159A1 (en) * | 2021-04-15 | 2022-10-20 | Merck Sharp & Dohme Llc | Rotavirus vectors for heterologous gene delivery |
| IL310628A (en) * | 2021-08-10 | 2024-04-01 | Icosavax Inc | Virus-like particle vaccine for respiratory syncytial virus |
| EP4410969A4 (en) * | 2021-09-29 | 2026-01-21 | Sk Bioscience Co Ltd | RECOMINED LIVE ATTENUATED RSV VACCINE STRAIN AND ITS PRODUCTION PROCESS |
| WO2023091766A2 (en) * | 2021-11-19 | 2023-05-25 | RNAimmune, Inc. | Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines |
| KR102785012B1 (ko) * | 2021-12-14 | 2025-03-20 | 경희대학교 산학협력단 | Rsv 항원 단백질을 포함하는 바이러스 유사입자 및 이를 이용한 백신 |
| WO2023208206A1 (zh) * | 2022-04-29 | 2023-11-02 | 北京新合睿恩生物医疗科技有限公司 | Rsv f蛋白突变体及其应用 |
| CN119452088A (zh) * | 2022-05-31 | 2025-02-14 | Vlp治疗日本公司 | 修饰疫苗设计开发 |
| US20260014242A1 (en) * | 2022-06-10 | 2026-01-15 | Glaxosmithkline Biologicals Sa | Rsv vaccination with trimeric rsv f fusion protein |
| WO2024041772A1 (en) * | 2022-08-22 | 2024-02-29 | Glaxosmithkline Biologicals Sa | Rsv-f proteins |
| JP2025532724A (ja) | 2022-09-29 | 2025-10-03 | ファイザー・インク | Ｒｓｖ ｆタンパク質三量体を含む免疫原性組成物 |
| CN116478296B (zh) * | 2022-10-17 | 2024-02-23 | 厦门大学 | 截短的呼吸道合胞病毒f蛋白及其用途 |
| EP4608441A1 (en) | 2022-10-27 | 2025-09-03 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| AU2023369585A1 (en) | 2022-10-27 | 2025-04-10 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
| EP4612173A1 (en) * | 2022-11-04 | 2025-09-10 | Sanofi Pasteur Inc. | Respiratory syncytial virus rna vaccination |
| WO2024100196A1 (en) * | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
| KR102531775B1 (ko) | 2022-11-11 | 2023-05-15 | 대한민국 | Rsv f 항체 또는 이의 항원 결합 단편 |
| CN116284266B (zh) * | 2022-11-21 | 2024-01-19 | 怡道生物科技(苏州)有限公司 | 突变型呼吸道合胞病毒融合前f蛋白及其应用 |
| WO2024115561A1 (en) * | 2022-12-01 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Vaccination against rsv |
| US20240252612A1 (en) | 2022-12-11 | 2024-08-01 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| EP4652184A2 (en) * | 2023-01-17 | 2025-11-26 | The Scripps Research Institute | Engineered paramyxovirus soluble fusion (f) proteins and related vaccines |
| PE20252308A1 (es) | 2023-01-18 | 2025-09-22 | Pfizer | Vacunas contra enfermedades respiratorias |
| WO2024164020A2 (en) * | 2023-02-03 | 2024-08-08 | The Trustees Of Columbia University In The City Of New York | Methods of inhibiting paramyxoviridae fusion to a target cell |
| CN120500351A (zh) * | 2023-02-03 | 2025-08-15 | 维纳根有限责任公司 | 呼吸道合胞病毒mRNA疫苗 |
| PE20252442A1 (es) * | 2023-02-21 | 2025-10-20 | Msd Int Business Gmbh | Proteinas de fusion de rsv trimericas estabilizadas sin un dominio de trimerizacion heterologo |
| WO2024175040A1 (en) * | 2023-02-22 | 2024-08-29 | Everest Medicines (China) Co., Ltd. | RSV mRNA VACCINES |
| WO2024193380A1 (zh) * | 2023-03-17 | 2024-09-26 | 成都威斯克生物医药有限公司 | 抗呼吸道合胞病毒感染的疫苗 |
| CN116536357A (zh) * | 2023-04-17 | 2023-08-04 | 中国医学科学院输血研究所 | 构建CRISPR/Cas12a中sgRNA剪切活性筛选系统的方法 |
| CN118108812B (zh) * | 2023-05-04 | 2025-04-15 | 国药中生生物技术研究院有限公司 | Rsv f蛋白的突变体 |
| CN118994329A (zh) * | 2023-05-18 | 2024-11-22 | 北京微星生物科技有限公司 | 融合前rsv f蛋白及其应用 |
| CN117050149B (zh) * | 2023-05-19 | 2025-12-12 | 珠海丽凡达生物技术有限公司 | 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用 |
| CN121263203A (zh) | 2023-05-19 | 2026-01-02 | 葛兰素史克生物有限公司 | 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法 |
| WO2024240267A1 (zh) * | 2023-05-25 | 2024-11-28 | 江苏瑞科生物技术股份有限公司 | 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽 |
| AU2024287014A1 (en) | 2023-06-07 | 2026-01-22 | Sichuan Clover Biopharmaceuticals, Inc. | Rsv vaccine composition, method and use thereof |
| WO2024256637A1 (en) * | 2023-06-16 | 2024-12-19 | Glaxosmithkline Biologicals Sa | Cysteine-substituted rsv-f proteins |
| TW202515531A (zh) | 2023-07-07 | 2025-04-16 | 美商輝瑞股份有限公司 | 兩親性ｔｌｒ７／８佐劑及其用途 |
| CN119431524A (zh) * | 2023-08-07 | 2025-02-14 | 北京新合睿恩生物医疗科技有限公司 | Rsv融合前构象f蛋白的突变体及其应用 |
| WO2025092933A1 (zh) * | 2023-10-31 | 2025-05-08 | 上海蓝鹊生物医药有限公司 | 一种rsv抗原、核酸、重组表达载体、药物组合物及其应用 |
| CN120022355A (zh) * | 2023-11-22 | 2025-05-23 | 长春百克生物科技股份公司 | 一种mRNA疫苗及其应用 |
| CN117304278B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025127857A1 (ko) * | 2023-12-15 | 2025-06-19 | 에스케이바이오사이언스(주) | 변이 rsv 단백질 |
| KR102816014B1 (ko) | 2023-12-20 | 2025-06-02 | 에스케이바이오사이언스(주) | Rsv 의 가용성 f 단백질을 생성하기 위한 재조합 전구체 폴리펩티드 및 이의 이용 |
| CN117586357B (zh) * | 2024-01-19 | 2024-07-09 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽 |
| CN117586425B (zh) * | 2024-01-19 | 2024-06-14 | 北京安百胜生物科技有限公司 | 一种重组呼吸道合胞病毒颗粒抗原其制备方法和应用 |
| CN117586359A (zh) * | 2024-01-19 | 2024-02-23 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽 |
| CN117567652B (zh) * | 2024-01-19 | 2024-05-14 | 北京安百胜生物科技有限公司 | 一种重组呼吸道合胞病毒颗粒抗原 |
| CN117645655B (zh) * | 2024-01-26 | 2024-05-24 | 普大生物科技(泰州)有限公司 | 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法 |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2025186719A1 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN118440937B (zh) * | 2024-04-09 | 2025-02-25 | 嘉译生物医药(杭州)有限公司 | 新型的人合胞病毒RSV B mRNA疫苗 |
| CN118496324B (zh) * | 2024-05-22 | 2025-10-21 | 苏州聚微生物科技有限公司 | RSV pre-F突变体及其生产方法和用途 |
| CN118580323B (zh) * | 2024-05-22 | 2025-06-17 | 苏州聚微生物科技有限公司 | Rsv融合前f蛋白的突变体及其制备和应用 |
| CN118406159B (zh) * | 2024-05-22 | 2025-07-08 | 苏州聚微生物科技有限公司 | RSV pre-F截短体及其生产方法和应用 |
| CN118480560B (zh) * | 2024-07-09 | 2024-11-26 | 北京悦康科创医药科技股份有限公司 | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 |
| CN119074910A (zh) * | 2024-08-30 | 2024-12-06 | 中国医学科学院病原生物学研究所 | 以麻疹减毒活疫苗为载体的重组呼吸道合胞病毒疫苗及其制备方法 |
| CN119176859B (zh) * | 2024-11-26 | 2025-03-14 | 北京成大天和生物科技有限公司 | 呼吸道合胞病毒f蛋白突变体及其应用 |
| CN120248057B (zh) * | 2024-12-26 | 2025-12-02 | 北京华诺泰生物医药科技有限公司 | 一种呼吸道合胞病毒f蛋白突变体及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2243234C2 (ru) * | 1996-07-12 | 2004-12-27 | Коннот Лабораториз Лимитед | Субъединичный вакцинный препарат респираторно-синцитиального вируса |
| WO2009079796A1 (en) * | 2007-12-24 | 2009-07-02 | Id Biomedical Corporation Of Quebec | Recombinant rsv antigens |
| WO2012158613A1 (en) * | 2011-05-13 | 2012-11-22 | Novartis Ag | Pre-fusion rsv f antigens |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US472209A (en) | 1892-04-05 | Vacuum-pan | ||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| CA1236641A (en) | 1984-07-06 | 1988-05-10 | Motoaki Tanaka | Copolymer of lactic acid and glycolic acid and method for producing same |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA1336955C (en) * | 1988-09-20 | 1995-09-12 | Peter R. Paradiso | Respiratory syncytial virus: vaccines and diagnostic assays |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| AU668384B2 (en) | 1992-03-12 | 1996-05-02 | Alkermes Controlled Therapeutics, Inc. | Controlled release ACTH containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| DK0667912T3 (da) | 1993-07-13 | 2008-11-10 | Centelion | Defekte adenovirusvektorer og anvendelse heraf i genterapi |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| CZ290331B6 (cs) | 1993-11-17 | 2002-07-17 | Laboratoires Om S. A. | Glukosaminové disacharidy, způsob jejich přípravy a farmaceutický prostředek |
| WO1995016772A1 (en) | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
| ES2267100T5 (es) | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | Oligonucleótidos inmunomoduladores. |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| EP1086234A1 (en) * | 1998-06-10 | 2001-03-28 | Incyte Pharmaceuticals, Inc. | New human carboxypeptidase inhibitor |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| WO2001046127A1 (fr) | 1999-12-22 | 2001-06-28 | Om Pharma | Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise |
| US6764685B1 (en) | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
| DE60139720D1 (de) | 2000-06-28 | 2009-10-08 | Glycofi Inc | Verfahren für die Herstellung modifizierter Glykoproteine |
| US20030232061A1 (en) | 2001-10-18 | 2003-12-18 | Fouchier Ronaldus Adrianus Maria | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| WO2002072012A2 (en) | 2001-03-09 | 2002-09-19 | Id Biomedical Corporation Of Quebec | A novel proteosome-liposaccharide vaccine adjuvant |
| ES2314042T3 (es) | 2001-04-17 | 2009-03-16 | Dainippon Sumitomo Pharma Co., Ltd. | Derivados nuevos de adenina. |
| EP1425045A4 (en) | 2001-09-13 | 2004-11-10 | Genvec Inc | ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| AU2002343462A1 (en) | 2001-10-01 | 2003-04-14 | Uab Research Foundation | Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof |
| EP1719511B1 (en) | 2001-11-16 | 2008-12-10 | 3M Innovative Properties Company | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof |
| WO2003072720A2 (en) | 2002-02-21 | 2003-09-04 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| JP2005533861A (ja) | 2002-07-25 | 2005-11-10 | メデュームン，インコーポレーテッド | 抗ＲＳＶ、抗ｈＭＰＶ、および抗ＰＩＶ抗体を使用するＲＳＶ、ｈＭＰＶ、およびＰＩＶの治療法と予防法 |
| EP1558747B1 (en) | 2002-10-16 | 2009-10-14 | The Scripps Research Institute | Glycoprotein synthesis |
| EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8 |
| JP2007525178A (ja) | 2003-04-25 | 2007-09-06 | メッドイミューン バクシーンズ，インコーポレイティド | メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法 |
| CN1813061B (zh) | 2003-04-25 | 2013-05-29 | 免疫医疗有限责任公司 | 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗 |
| US8637234B2 (en) | 2004-04-16 | 2014-01-28 | Uab Research Foundation | Molecular scaffolds for HIV-1 epitopes |
| WO2006091455A2 (en) | 2005-02-18 | 2006-08-31 | Uab Research Foundation | Molecular scaffolds for hiv-1 immunogens |
| CN101548009A (zh) | 2005-03-10 | 2009-09-30 | 米迪缪尼有限公司 | 偏肺病毒株及其在疫苗制备和作为抗原序列表达载体的应用以及增殖该病毒的方法 |
| US7728106B2 (en) | 2005-07-01 | 2010-06-01 | University Of Maryland Biotechnology Institute | HIV-1 glycopeptides and derivatives; preparation and applications thereof |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| US20100068217A1 (en) | 2006-08-25 | 2010-03-18 | Kwong Peter D | Epitope-transplant scaffolds and their use |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| WO2009012155A2 (en) | 2007-07-13 | 2009-01-22 | Medimmune, Llc | Preparation of negative-stranded rna viruses by electroporation |
| EP2604695B1 (en) | 2007-12-27 | 2022-11-16 | Universität Zürich | Replication-defective arenavirus vectors |
| WO2010075491A2 (en) * | 2008-12-24 | 2010-07-01 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
| CA2760465A1 (en) | 2009-05-12 | 2010-11-18 | Transgene Sa | Method for orthopoxvirus production and purification |
| CA2766211A1 (en) | 2009-06-24 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
| KR20120093811A (ko) * | 2009-06-24 | 2012-08-23 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 백신 |
| ES2991844T3 (es) | 2009-07-15 | 2024-12-05 | Glaxosmithkline Biologicals Sa | Composiciones de proteína F de VRS y métodos para producir las mismas |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| CN102712692B (zh) | 2009-10-06 | 2014-12-31 | 医学免疫有限公司 | Rsv-特异性结合分子 |
| WO2011050168A2 (en) | 2009-10-21 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Rsv immunogens, antibodies and compositions thereof |
| CN102210860B (zh) | 2011-05-31 | 2012-11-21 | 昆明理工大学 | 一种结核分枝杆菌tb10．4-f1融合蛋白疫苗及制备方法 |
| ES2395677B1 (es) * | 2011-07-29 | 2013-12-26 | Instituto De Salud Carlos Iii | Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma. |
| AU2013301312A1 (en) * | 2012-08-06 | 2015-03-19 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against RSV and B. pertussis |
| EA201590683A1 (ru) * | 2012-11-20 | 2015-11-30 | Глаксосмитклайн Байолоджикалс С.А. | Тримеры rsv f, предшествующие слиянию |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| AU2014243756B2 (en) * | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| US9856313B2 (en) | 2013-03-15 | 2018-01-02 | Xiamen University | Epitope of RSV fusion protein and antibody recognizing the same |
| US10899800B2 (en) | 2013-04-25 | 2021-01-26 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
-
2014
- 2014-03-13 AU AU2014243756A patent/AU2014243756B2/en active Active
- 2014-03-13 DK DK14775224.0T patent/DK2970398T3/da active
- 2014-03-13 SI SI201432090T patent/SI2970398T1/sl unknown
- 2014-03-13 KR KR1020227033808A patent/KR102766946B1/ko active Active
- 2014-03-13 SM SM20240297T patent/SMT202400297T1/it unknown
- 2014-03-13 WO PCT/US2014/026714 patent/WO2014160463A1/en not_active Ceased
- 2014-03-13 PL PL14775224.0T patent/PL2970398T3/pl unknown
- 2014-03-13 JP JP2016502221A patent/JP6703475B2/ja active Active
- 2014-03-13 KR KR1020157025199A patent/KR102450375B1/ko active Active
- 2014-03-13 HR HRP20240996TT patent/HRP20240996T1/hr unknown
- 2014-03-13 LT LTEPPCT/US2014/026714T patent/LT2970398T/lt unknown
- 2014-03-13 KR KR1020257003905A patent/KR20250023601A/ko active Pending
- 2014-03-13 RS RS20240825A patent/RS65760B1/sr unknown
- 2014-03-13 CN CN202110068562.XA patent/CN112851766A/zh active Pending
- 2014-03-13 CN CN201480027499.3A patent/CN105473604B/zh active Active
- 2014-03-13 PT PT147752240T patent/PT2970398T/pt unknown
- 2014-03-13 CA CA2902877A patent/CA2902877A1/en active Pending
- 2014-03-13 RU RU2015142981A patent/RU2761631C2/ru active
- 2014-03-13 FI FIEP14775224.0T patent/FI2970398T3/fi active
- 2014-03-13 EP EP14775224.0A patent/EP2970398B1/en active Active
- 2014-03-13 US US14/776,651 patent/US10017543B2/en active Active
- 2014-03-13 EP EP24174501.7A patent/EP4421177A3/en active Pending
- 2014-03-13 ES ES14775224T patent/ES2981623T3/es active Active
- 2014-03-13 HU HUE14775224A patent/HUE067333T2/hu unknown
- 2014-03-13 MX MX2015013065A patent/MX385818B/es unknown
-
2015
- 2015-09-11 MX MX2021010519A patent/MX2021010519A/es unknown
-
2018
- 2018-07-02 US US16/025,858 patent/US11130785B2/en active Active
- 2018-12-21 AU AU2018282476A patent/AU2018282476B2/en active Active
-
2020
- 2020-02-12 JP JP2020021468A patent/JP7043530B2/ja active Active
-
2021
- 2021-03-08 AU AU2021201468A patent/AU2021201468B2/en active Active
- 2021-09-17 US US17/478,533 patent/US20220002351A1/en not_active Abandoned
-
2022
- 2022-03-16 JP JP2022041006A patent/JP7503588B2/ja active Active
-
2023
- 2023-02-09 AU AU2023200712A patent/AU2023200712B2/en active Active
- 2023-09-11 US US18/464,786 patent/US11981707B2/en active Active
-
2024
- 2024-06-10 JP JP2024093392A patent/JP2024107243A/ja active Pending
- 2024-12-30 US US19/005,704 patent/US20250368690A1/en active Pending
-
2025
- 2025-05-19 AU AU2025203614A patent/AU2025203614A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2243234C2 (ru) * | 1996-07-12 | 2004-12-27 | Коннот Лабораториз Лимитед | Субъединичный вакцинный препарат респираторно-синцитиального вируса |
| WO2009079796A1 (en) * | 2007-12-24 | 2009-07-02 | Id Biomedical Corporation Of Quebec | Recombinant rsv antigens |
| WO2012158613A1 (en) * | 2011-05-13 | 2012-11-22 | Novartis Ag | Pre-fusion rsv f antigens |
Non-Patent Citations (1)
| Title |
|---|
| MARGO M. et al., Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention, Proc. Natl. Acad. Sci. USA, 2012, V.109, N.8, p.3089-3094. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021201468B2 (en) | Prefusion rsv f proteins and their use | |
| US10858400B2 (en) | Prefusion RSV F proteins and their use | |
| KR20220134622A (ko) | 코로나바이러스 감염 예방 및 치료용 조성물 및 방법 - sars-cov-2 백신 | |
| US20230174587A1 (en) | Recombinant human metapneumovirus f proteins and their use | |
| US11566050B2 (en) | Methods and compositions for norovirus vaccines and diagnostics | |
| CN110678202A (zh) | 用于体内核酸表达的系统和方法 | |
| WO2021188818A1 (en) | Vaccine constructs and compositions and methods of use thereof | |
| RU2852571C2 (ru) | Белки rsv f в предшествующей слиянию конформации и их применение | |
| WO2024155381A1 (en) | Antibodies for zika virus | |
| WO2024197134A1 (en) | Coronavirus spike protein-based vaccines | |
| BR112015022375B1 (pt) | Imunógenos isolados de proteína f de rsv e seu uso, partícula similar a vírus, nanopartícula de proteína, molécula de ácido nucleico, vetor, célula hospedeira isolada bacteriana ou de levedura, composição imunogênica e kit |